clofibric acid has been researched along with Familial Combined Hyperlipidemia in 11 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atorvastatin monotherapy has a better effect on LDL-C and apoprotein B than statin-fibrate combinations, but a lesser effect on HDL-C, TG and in the case of ciprofibrate combinations, fibrinogen." | 2.70 | Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. ( Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN, 2002) |
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| " Physical and laboratory investigations for adverse effects were performed every month for the first 3 months and every 3 months thereafter." | 2.68 | Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. ( Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kapoor, SK | 1 |
| Kataria, H | 1 |
| Patra, SR | 1 |
| Boruah, T | 1 |
| Rubenfire, M | 1 |
| Brook, RD | 1 |
| Rosenson, RS | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 1 |
| Wray, R | 1 |
| Bartz, VT | 1 |
| Gatz, J | 1 |
| Slotty, C | 1 |
| Schröter, C | 1 |
| Töle, R | 1 |
| Wand, P | 1 |
| Bruckert, E | 2 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Kontopoulos, AG | 4 |
| Athyros, VG | 4 |
| Papageorgiou, AA | 4 |
| Hatzikonstandinou, HA | 2 |
| Mayroudi, MC | 1 |
| Boudoulas, H | 1 |
| Didangelos, TP | 1 |
| Carina, MV | 1 |
| Kranitsas, DF | 1 |
| Turay, J | 1 |
| Grniaková, V | 1 |
| Valka, J | 1 |
| Athyrou, VV | 1 |
| Demitriadis, DS | 1 |
| Pehlivanidis, AN | 1 |
3 reviews available for clofibric acid and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combinatio | 2010 |
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
[Treatment of familial combined hyperlipidemia].
Topics: Clinical Protocols; Clofibric Acid; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Comb | 1997 |
6 trials available for clofibric acid and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
[Long-term treatment of hyperlipoproteinemia with etofibrate].
Topics: Clofibric Acid; Follow-Up Studies; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; | 1993 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
Topics: Adult; Analysis of Variance; Clofibric Acid; Coronary Disease; Double-Blind Method; Drug Therapy, Co | 1996 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Thera | 1997 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibro | 2002 |
2 other studies available for clofibric acid and Familial Combined Hyperlipidemia
| Article | Year |
|---|---|
Orthopaedic/radiology/pathology conference: Multiple nodular outgrowths in the hands and feet of a 60-year-old man.
Topics: Biopsy; Clofibric Acid; Combined Modality Therapy; Diagnosis, Differential; Foot Diseases; Hand Defo | 2010 |
Changes in paraoxonase and apolipoprotein A-I, B, C-III and E in subjects with combined familiar hyperlipoproteinemia treated with ciprofibrate.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Apolipoproteins | 2000 |